Increased risk of fatty liver disease with proton pump inhibitors
- PDF / 151,157 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 97 Downloads / 252 Views
1
Increased risk of fatty liver disease with proton pump inhibitors Use of proton-pump inhibitors (PPIs) is associated with an increased risk of fatty liver disease, according to a study from South Korea. The nation-wide cohort study investigated the association between PPI use and the risk of fatty liver disease using 2002–2015 data from a sample of 155 596 individuals obtained from the Korean National Health Insurance ServiceNational Sample Cohort. Of the 75 727 individuals who had at least one PPI prescription during 1 463 556 person-years of follow-up, 3735 individuals developed fatty liver disease. Cox regression modelling showed that PPI users were significantly more likely to develop fatty liver disease compared to non-PPI users (hazard ratio [HR] 1.68; [95% CI 1.61–1.75]). After adjusting for various confounders, including age, gender, BMI, smoking, alcohol intake, comorbidities, exercise and income levels, the association between PPI use and fatty liver disease was still significant (HR 1.50; 95% CI 1.44–1.57). Importantly, prolonged PPI use was associated with a significantly increased dose-dependent risk of fatty liver disease until 180 days of PPI use. Analyses of subgroups defined by age, gender, alcohol intake and various comorbidities showed that the increased risk of fatty liver disease among PPI users was consistently observed across all subgroups. Long-term use of PPIs in individuals at high risk of fatty liver disease should be avoided, suggest the researchers. Pyo JH, et al. Proton Pump Inhibitors Use and the Risk of Fatty Liver Disease. A Nationwide Cohort Study. Journal of Gastroenterology and Hepatology : 4 Sep 2020. 803502160 Available from: URL: http://doi.org/10.1111/jgh.15236
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Sep 2020 No. 1822
Data Loading...
